O-GlcNAcylation: A New Cancer Hallmark ? - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Frontiers in Endocrinology Année : 2013

O-GlcNAcylation: A New Cancer Hallmark ?


O-linked N-acetylglucosaminylation (O-GlcNAcylation) is a reversible post-translational modification consisting in the addition of a sugar moiety to serine/threonine residues of cytosolic or nuclear proteins. Catalyzed by O-GlcNAc-transferase (OGT) and removed by O-GlcNAcase, this dynamic modification is dependent on environmental glucose concentration. O-GlcNAcylation regulates the activities of a wide panel of proteins involved in almost all aspects of cell biology. As a nutrient sensor, O-GlcNAcylation can relay the effects of excessive nutritional intake, an important cancer risk factor, on protein activities and cellular functions. Indeed, O-GlcNAcylation has been shown to play a significant role in cancer development through different mechanisms. O-GlcNAcylation and OGT levels are increased in different cancers (breast, prostate, colon…) and vary during cell cycle progression. Modulating their expression or activity can alter cancer cell proliferation and/or invasion. Interestingly, major oncogenic factors have been shown to be directly O-GlcNAcylated (p53, MYC, NFκB, β-catenin…). Furthermore, chromatin dynamics is modulated by O-GlcNAc. DNA methylation enzymes of the Tet family, involved epigenetic alterations associated with cancer, were recently found to interact with and target OGT to multi-molecular chromatin-remodeling complexes. Consistently, histones are subjected to O-GlcNAc modifications which regulate their function. Increasing number of evidences point out the central involvement of O-GlcNAcylation in tumorigenesis, justifying the attention received as a potential new approach for cancer treatment. However, comprehension of the underlying mechanism remains at its beginnings. Future challenge will be to address directly the role of O-GlcNAc-modified residues in oncogenic-related proteins to eventually propose novel strategies to alter cancer development and/or progression.
Fichier principal
Vignette du fichier
fendo-04-00099.pdf (2.35 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03173298 , version 1 (18-03-2021)


Paternité - CC BY 4.0



Yann Fardini, Vanessa Dehennaut, Tony Lefebvre, Tarik Issad. O-GlcNAcylation: A New Cancer Hallmark ?. Frontiers in Endocrinology, 2013, 4, pp.99. ⟨10.3389/fendo.2013.00099⟩. ⟨hal-03173298⟩
39 Consultations
46 Téléchargements



Gmail Facebook Twitter LinkedIn More